Glenn Novarro
Glenn Novarro
aggressive approach clearly poor took
What is disappointing is that Abbott took a very aggressive approach with this drug, ... They clearly made a poor decision.
continue crippling despite earnings effects fiscal forecast growth per sales share solid throughout
We continue to forecast solid low-to-mid-teens sales growth and high-teens earnings per share growth throughout fiscal 2001 despite the crippling effects of the (weak) euro,
both cleaner compelling data expecting investors reflective stock weakness
Today's weakness in the stock is reflective of investors expecting more compelling and cleaner data from both trials,
fda hope learn letter status
We hope to learn more about the status of the FDA letter on Tuesday.
believe company confidence delivering earnings outlook remains respect strongest
Overall, we believe that the earnings outlook for Medtronic is the strongest in the industry, and Medtronic remains the one company that we have the most confidence in with respect to delivering on its earnings guidance,